Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1

NCT02032004 is registered in ClinicalTrials.gov with Mesoblast, Inc. as lead sponsor.

NCT NCT02032004
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02032004 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind, Randomized, Sham-procedure-controlled, Parallel-Group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) in Chronic Heart Failure Due to LV Systolic Dysfunction (Ischemic or Nonischemic) Dream HF-1
Lead sponsor
Mesoblast, Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 3, 2014
Completion date
January 30, 2020
Enrollment
565 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure